1. Market Research
  2. > Pharmaceutical Market Trends
  3. > RAPID Pharmaceuticals AG - Product Pipeline Review - 2014

RAPID Pharmaceuticals AG - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 22 pages

RAPID Pharmaceuticals AG - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘RAPID Pharmaceuticals AG - Product Pipeline Review - 2014’, provides an overview of the RAPID Pharmaceuticals AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RAPID Pharmaceuticals AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of RAPID Pharmaceuticals AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of RAPID Pharmaceuticals AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the RAPID Pharmaceuticals AG’s pipeline products

Reasons to buy

- Evaluate RAPID Pharmaceuticals AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of RAPID Pharmaceuticals AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the RAPID Pharmaceuticals AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of RAPID Pharmaceuticals AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of RAPID Pharmaceuticals AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of RAPID Pharmaceuticals AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

RAPID Pharmaceuticals AG - Product Pipeline Review - 2014
Table of Contents
RAPID Pharmaceuticals AG Snapshot 4
RAPID Pharmaceuticals AG Overview 4
Key Information 4
Key Facts 4
RAPID Pharmaceuticals AG - Research and Development Overview 5
Key Therapeutic Areas 5
RAPID Pharmaceuticals AG - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
RAPID Pharmaceuticals AG - Pipeline Products Glance 9
RAPID Pharmaceuticals AG - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
RAPID Pharmaceuticals AG - Drug Profiles 11
RAP-102 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
RAP-103 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
RAP-310 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
RAP-701 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
RAPID Pharmaceuticals AG - Pipeline Analysis 15
RAPID Pharmaceuticals AG - Pipeline Products by Target 15
RAPID Pharmaceuticals AG - Pipeline Products by Route of Administration 16
RAPID Pharmaceuticals AG - Pipeline Products by Molecule Type 17
RAPID Pharmaceuticals AG - Pipeline Products by Mechanism of Action 18
RAPID Pharmaceuticals AG - Dormant Projects 19
RAPID Pharmaceuticals AG - Locations And Subsidiaries 20
Head Office 20
Other Locations and Subsidiaries 20
Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

List of Tables

RAPID Pharmaceuticals AG, Key Information 4
RAPID Pharmaceuticals AG, Key Facts 4
RAPID Pharmaceuticals AG - Pipeline by Indication, 2014 6
RAPID Pharmaceuticals AG - Pipeline by Stage of Development, 2014 7
RAPID Pharmaceuticals AG - Monotherapy Products in Pipeline, 2014 8
RAPID Pharmaceuticals AG - Preclinical, 2014 9
RAPID Pharmaceuticals AG - Discovery, 2014 10
RAPID Pharmaceuticals AG - Pipeline by Target, 2014 15
RAPID Pharmaceuticals AG - Pipeline by Route of Administration, 2014 16
RAPID Pharmaceuticals AG - Pipeline by Molecule Type, 2014 17
RAPID Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2014 18
RAPID Pharmaceuticals AG - Dormant Developmental Projects,2014 19
RAPID Pharmaceuticals AG, Subsidiaries 20

List of Figures

RAPID Pharmaceuticals AG - Pipeline by Top 10 Indication, 2014 6
RAPID Pharmaceuticals AG - Pipeline by Stage of Development, 2014 7
RAPID Pharmaceuticals AG - Monotherapy Products in Pipeline, 2014 8
RAPID Pharmaceuticals AG - Pipeline by Top 10 Target, 2014 15
RAPID Pharmaceuticals AG - Pipeline by Top 10 Route of Administration, 2014 16
RAPID Pharmaceuticals AG - Pipeline by Top 10 Molecule Type, 2014 17
RAPID Pharmaceuticals AG - Pipeline Products by Top 10 Mechanism of Action, 2014 18

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.